Plus, news about uniQure, MBX Biosciences, KalVista, Volastra, Basilea Pharmaceutica, Gossamer Bio, Respira Therapeutics, Sanofi, Immuneering and Heidelberg Pharma:
🫀 Kardigan reveals its pipeline: The cardiovascular biotech has in-licensed three clinical-stage assets for undisclosed terms ...
↧
Kardigan gets the rights to a MyoKardia drug; Lilly stops Phase 2 trial for muscle-sparing candidate
↧